Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
SAN CARLOS, Calif., Sept. 02, 2024 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call ...
| Ticker |
Sentiment |
Impact |
|
PCVX
|
Somewhat Bullish
|
58 %
|
|
STRO
|
Neutral
|
9 %
|
